Capillary isoelectric focusing (cIEF) is a high-resolution analytical technique that can separate protein/peptide mixtures, protein glycoforms, and other charge variants based on isoelectric point (pI). CD Formulation integrates cutting-edge cIEF technology into our protein/peptide characterization technology platform to provide precise insights for your biopharmaceutical development program. With our cIEF technology, you can obtain critical information about protein charge characteristics, glycoform changes, and other structural variants to support formulation development, product stability assessment, and to prove the identity of protein drugs in quality control (QC) and release testing.
cIEF is a powerful analytical technique used primarily to separate and characterize biomolecules, especially proteins and peptides, based on their isoelectric point (pI). The technique is primarily performed in polyacrylamide gels. To separate molecules based on their pI, a pH gradient is established within the gel via a mixture of ampholytes. The target molecules migrate along the electric field until they reach the pH corresponding to their pI, at which point the net charge of the molecule is zero and migration ceases. The UV absorbance is measured across the capillary throughout the separation, allowing real-time observation and eventual quantification.
cIEF is based on the principle of capillary gel electrophoresis (cGE), which combines the principles of isoelectric focusing with those of capillary electrophoresis to achieve high-resolution separation in a very short time. Electrophoresis is an electric field-driven separation technique that uses the property of charged molecules to move in an electric field. When different molecules in a sample, such as proteins, peptides, ions, etc., are subjected to an electric field, they will migrate at different speeds due to their different charges, sizes, and shapes, thereby achieving separation.
Compared with conventional isoelectric focusing (IEF), cIEF has higher resolution, faster sample analysis speed, and a detection limit that is approximately 10 times lower.
Fig. 1 Principle of capillary isoelectric focusing (cIEF). (CD Formulation)
Thanks to decades of experience in supporting protein/peptide biopharmaceutical development and manufacturing using cIEF technology, our team of highly qualified experts offers a range of cIEF-related services to accelerate the implementation and success of your projects.
During the development and production of protein biologics, charge variants of the target protein may arise due to post-translational modifications (PTMs) and degradation. Our scientists rely on cIEF to quantify the charge variants present at different stages of protein and peptide drug development and manufacturing, including cell line selection, stability studies, formulation development, and upstream and downstream process monitoring.
Utilizing cutting-edge cIEF technology, we support the following protein/peptide characterization plans, including but not limited to:
cIEF can effectively separate proteins based on their isoelectric point in a pH gradient. Knowing the pI is essential for understanding protein structure, stability, and interactions.
Many therapeutic proteins, including monoclonal antibodies, exhibit charge variants due to post-translational modifications (PTMs) such as glycosylation, phosphorylation, or deamidation. cIEF provides high resolution of these charge variants, enabling detailed characterization.
By analyzing the charge distribution of a protein, cIEF can help identify impurities such as aggregates or fragments, thereby enhancing the assessment of protein purity.
cIEF can be used to study the effects of PTMs on protein behavior and stability. Differences in pI due to modifications can be quantitatively assessed.
The stability of a protein can be linked to its charge properties. By performing cIEF under various conditions (e.g., pH, temperature), researchers can assess how environmental factors affect protein stability and aggregation behavior.
In biopharmaceutical development, cIEF can help screen formulation conditions to minimize the formation of charge variants, resulting in a more stable protein product.
cIEF is often part of a routine QC analytical strategy for therapeutic proteins to ensure consistency in product formulation and identify any variations in production batches.
In our analytical laboratory, cIEF is typically performed on polyacrylamide gels. A brief working procedure is as follows:
Fig. 2 Workflow for cIEF analysis. (CD Formulation)
Published Data
Technology: CIEF-MS
Journal:Methods Mol Biol.
IF: 4.2
Published: 2022
Results:
The authors developed a novel online capillary isoelectric focusing mass spectrometry (CIEF-MS) method for charge variant analysis of monoclonal antibodies (mAbs). The method uses a commercial EMASS-II CE-MS ion source based on electrokinetic pumping sheath technology to address the challenges of traditional CE-MS interfaces. Trastuzumab, bevacizumab, infliximab, and cetuximab were selected as model proteins for CIEF-MS validation and compared with images obtained by the iCIEF-UV method.
A comparison of the CIEF-MS analysis of bevacizumab with the iCIEF-UV analysis is shown below:
Fig. 3 Bevacizumab CIEF-MS analysis in comparison with iCIEF-UV. (Dai J, et al., 2022)
CD Formulation aims to provide a powerful analytical tool for the separation, purification, and characterization of proteins and peptides. Please feel free to contact us if you are interested in our services. Learn how our cIEF technology can support the smooth implementation of your protein/peptide biopharmaceutical program.
References